PODROCK™ O

PODROCK™ O delivers a pharmacologically complementary dual-mechanism combination: Cefpodoxime 200mg (third-generation cephalosporin with MSSA activity, PBP-mediated cell wall synthesis inhibition) + Ofloxacin 200mg (fluoroquinolone, dual DNA gyrase + topoisomerase IV inhibition causing lethal DNA strand breaks).

This combination covers three distinct bacterial domains simultaneously from two different bacterial targets:
1. Gram-positive organisms (S. pneumoniae, MSSA, streptococci) — primarily from cefpodoxime's PBP binding
2. Gram-negative aerobes (E. coli, Klebsiella, H. influenzae, Pseudomonas) — covered by both agents with synergistic kill rates
3. Atypical organisms (Chlamydia, Mycoplasma) — covered by ofloxacin's intracellular penetration

The two-target attack on gram-negative organisms (cell wall from cefpodoxime, DNA replication from ofloxacin) achieves synergistic bactericidal activity that is particularly valuable for high-inoculum infections like pyelonephritis and complicated sinusitis where rapid, complete bacterial clearance is clinically important. The combination also significantly reduces the risk of resistance emergence during therapy — an organism would need simultaneous mutations in both PBP genes and topoisomerase genes to survive, a probability near zero in clinical settings.

PODROCK™ O is indicated for moderate-to-severe polymicrobial and resistant infections requiring both cephalosporin and fluoroquinolone activity in a convenient single-tablet formulation.

Complicated Urinary Tract Infections and Pyelonephritis: The most important indication. E. coli and Klebsiella UTIs involving organisms partially resistant to either agent alone are covered by the synergistic dual-mechanism combination. Ofloxacin's exceptional urine concentrations combined with cefpodoxime's gram-negative cell wall activity achieve comprehensive bacteriuria eradication.

Respiratory Tract Infections: Community-acquired pneumonia and severe acute exacerbations of COPD where both typical (S. pneumoniae, H. influenzae) and atypical organisms (Mycoplasma, Chlamydia) must be covered empirically. Cefpodoxime covers pneumococcal and H. influenzae; ofloxacin covers atypicals and provides additional gram-negative cover.

ENT Infections: Complicated sinusitis and chronic suppurative otitis media with mixed gram-positive/gram-negative/atypical aetiology.

Sexually Transmitted Infections: Uncomplicated gonorrhoea (cefpodoxime) + chlamydial co-infection (ofloxacin) — a common co-infection pair that this combination treats simultaneously.

Skin Infections: Moderate-to-severe skin infections with polymicrobial gram-positive and gram-negative involvement.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.